NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Klotho Neurosciences Inc (KLTO) Stock Analysis

Klotho Neurosciences Inc (KLTO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KLTO

$0.52

+$0.00 (+0.81%)

Last trade March 11, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KLTO with… →

KLTO Key Statistics

As of Mar 11, 2026
Trading
Open
$0.53
Previous Close
$0.52
Day's Range
0.46–0.53
52-Week Range
0.11–3.91
Volume
2.18M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.23
Valuation
Market Cap
$56.66M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.30
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+85.23%
Dividend and dates
Avg Volume
2.41M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KLTO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+81.38%
2025−39.79%

As of March 11, 2026.

KLTO Valuation vs Biotechnology Median

Median of 656 stocks
MetricKLTOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Klotho Neurosciences Inc (KLTO) is capitalised at $56.66M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 3.

KLTO last closed at $0.52 on March 11, 2026. That is $0.00 (+0.81%) against the previous close. Over the past 52 weeks the price has ranged from $0.11 to $3.91. The latest close sits 361.85% above that 52-week low.

Financial Health

The reported profit margin is 0%. Trailing earnings per share are −0.3.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +85.23%. The reported beta is 2.24. Daily returns over the trailing 1 year annualize to a volatility of 814.53%.

Growth & Income

The record shows no dividend for KLTO.

So far in 2026 the price is +81.38%. The record holds one complete calendar year, 2025, which returned −39.79%.

Peer Comparison

Klotho Neurosciences Inc (KLTO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Klotho Neurosciences Inc KLTO $56.66M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Klotho Neurosciences Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of March 11, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Klotho Neurosciences Inc

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Visit website →